S&P 500   3,847.63
DOW   31,129.74
QQQ   323.57
S&P 500   3,847.63
DOW   31,129.74
QQQ   323.57
S&P 500   3,847.63
DOW   31,129.74
QQQ   323.57
S&P 500   3,847.63
DOW   31,129.74
QQQ   323.57
Log in
ASX:SOM

SomnoMed Limited (SOM.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$1.08
MA: A$1.08
A$1.08
52-Week Range N/A
Volume95,124 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific Region. Its products include SomnoDent, an oral appliance for obstructive sleep apnea; and SomnoBrux, a mouthguard for the treatment of teeth grinding damage, as well as SomTabs for cleaning its devices. The company was founded in 2004 and is based in Crows Nest, Australia.

MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9467 0400
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$57.30 million
Book ValueA$0.41 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive SOM News and Ratings via Email

Sign-up to receive the latest news and ratings for SOM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











SomnoMed Limited (SOM.AX) (ASX:SOM) Frequently Asked Questions

What stocks does MarketBeat like better than SomnoMed Limited (SOM.AX)?

Wall Street analysts have given SomnoMed Limited (SOM.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but SomnoMed Limited (SOM.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of SomnoMed Limited (SOM.AX)'s key competitors?

Who are SomnoMed Limited (SOM.AX)'s key executives?

SomnoMed Limited (SOM.AX)'s management team includes the following people:
  • Mr. Neil Verdal-Austin, CEO, MD & Director
  • Mr. Hervé Fiévet, Chief Financial Officer
  • Mr. Mark Harding, VP of Global Marketing
  • Mr. Martin Weiland, Exec. VP of Sales and Marketing - Europe
  • Mr. Matthew Conlon, Exec. VP Sales & Marketing - North America
  • Dr. Jagdeep Bijwadia, Chief Medical Officer
  • Mr. Terence A. Flitcroft, Company Sec. (Age 61)
  • Dr. Peter Spencer MBA Ph.D., MAICD, Gen. Mang. of Operations (Age 64)
  • Mr. Christopher Bedford, VP of Global Production and Product Devel.

What is SomnoMed Limited (SOM.AX)'s stock symbol?

SomnoMed Limited (SOM.AX) trades on the ASX under the ticker symbol "SOM."

How big of a company is SomnoMed Limited (SOM.AX)?

SomnoMed Limited (SOM.AX) has a market capitalization of $0.00 and generates $57.30 million in revenue each year.

What is SomnoMed Limited (SOM.AX)'s official website?

The official website for SomnoMed Limited (SOM.AX) is somnomed.com.

How can I contact SomnoMed Limited (SOM.AX)?

The company can be reached via phone at 61 2 9467 0400.

This page was last updated on 1/20/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.